Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Metastatic Colorectal Cancer (CRC) participants in the Flatiron database as defined by:
Diagnosed with CRC (ICD-9 153.x or 154.x or ICD-10 C18x, or C19x, or C20x, or C21x)
Pathology consistent with CRC
At least two documented clinical visits on or after January 1, 2013
Evidence of Stage IV or recurrent metastatic CRC diagnosed on or after January 1, 2013
Participants with high levels of microsatellite instability (MSI-H) and/or mismatch repair (MMR) protein deficiency (dMMR)
Participants who received 2L therapy of interest on or after the initial mCRC diagnosis date
Participants who had at least 1 month medical data during the prior to and post periods; however, participants who died within 1 month after the index date will not be excluded from the study
You may not be if
Participants \<18 years of age at index date
Participants who received clinical trial drug during the prior or post periods
Clareo Health | A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
